Ana Sofia Varanda

Ana Sofia Varanda

Auto-generated profile, based on publicly available information

Ana Sofia Varanda

Expression Regulation in Cancer, Instituto de Investigação e Inovação em Saúde, University of Porto, Portugal; Institute of Molecular Pathology and Immunology University of Porto (IPATIMUP), Porto, Portugal; Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMarisa Pereira
Marisa Pereira
SFStephany Francisco
Stephany Francisco
AVAna Sofia Varanda
Ana Sofia Varanda
MSMafalda Santos
Mafalda Santos
MSManuel Santos
Manuel Santos
ASAna Soares
Ana Soares
Transfer RNAs (tRNAs) are key players of protein synthesis, as they decode the genetic information organized in mRNA codons, translating them into the code of 20 amino acids. To be fully active, tRNAs undergo extensive post-transcriptional modifications, catalyzed by different tRNA-modifying enzymes. Lack of these modifications increases the level of missense errors and affects codon decoding rate, contributing to protein aggregation with deleterious consequences to the cell. Recent works show that tRNA hypomodification and tRNA-modifying-enzyme deregulation occur in several diseases where proteostasis is affected, namely, neurodegenerative and metabolic diseases. In this review, we discuss the recent findings that correlate aberrant tRNA modification with proteostasis imbalances, in particular in neurological and metabolic disorders, and highlight the association between tRNAs, their modifying enzymes, translational decoding, and disease onset.

1 October 2019 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
MSMafalda Santos
Mafalda Santos
AFAna Fidalgo
Ana Fidalgo
AVA. Sofia Varanda
A. Sofia Varanda
COCarla Oliveira
Carla Oliveira
MSManuel Santos
Manuel Santos

7 June 2018 in RNA Biology
Verified
Journal Article
Closed access
MSMafalda Santos
Mafalda Santos
PPPatricia M. Pereira
Patricia M. Pereira
AVA. Sofia Varanda
A. Sofia Varanda
JCJoana Carvalho
Joana Carvalho
MAMafalda Azevedo
Mafalda Azevedo
MSManuel Santos
Manuel Santos
Deregulation of tRNAs, aminoacyl-tRNA synthetases and tRNA modifying enzymes are common in cancer, raising the hypothesis that protein synthesis efficiency and accuracy (mistranslation) are compromised in tumors. We show here that human colon tumors and xenograft tumors produced in mice by two epithelial cancer cell lines mistranslate 2- to 4-fold more frequently than normal tissue. To clarify if protein mistranslation plays a role in tumor biology, we expressed mutant Ser-tRNAs that misincorporate Ser-at-Ala (frequent error) and Ser-at-Leu (infrequent error) in NIH3T3 cells and investigated how they responded to the proteome instability generated by the amino acid misincorporations. There was high tolerance to both misreading tRNAs, but the Ser-to-Ala misreading tRNA was a more potent inducer of cell transformation, stimulated angiogenesis and produced faster growing tumors in mice than the Ser-to-Leu misincorporating tRNA. Upregulation of the Akt pathway and the UPR were also observed. Most surprisingly, the relative expression of both misreading tRNAs increased during tumor growth, suggesting that protein mistranslation is advantageous in cancer contexts. These data highlight new features of protein synthesis deregulation in tumor biology.

5 March 2018 in Biotechnology Journal
Verified
Journal Article
Open access
PDF file
MPMarisa Pereira
Marisa Pereira
DTDiogo Tomé
Diogo Tomé
ADAna S. Domingues
Ana S. Domingues
AVAna S. Varanda
Ana S. Varanda
CPCristiana Paulo
Cristiana Paulo
ASAna Soares
Ana Soares
Protein conformational disorders are characterized by disruption of protein folding and toxic accumulation of protein aggregates. Here we describe a sensitive and simple method to follow and monitor general protein aggregation in human cells. Heat shock protein 27 (HSP27) is an oligomeric small heat shock protein that binds and keeps unfolded proteins in a folding competent state. This high specificity of HSP27 for aggregated proteins can be explored to monitor aggregation in living cells by fusing it to a fluorescent protein as Green Fluorescent Protein (GFP). We have constructed a HeLa stable cell line expressing a HSP27:GFP chimeric reporter protein and after validation, this stable cell line is exposed to different agents that interfere with proteostasis, namely Arsenite, MG132, and Aβ‐peptide. Exposure to proteome destabilizers lead to re‐localization of HSP27:GFP fluorescence to foci, confirming that our reporter system is functional and can be used to detect and follow protein aggregation in living cells. This reporter is a valuable tool to setup wide‐genetic screens to identify genes and pathways involved in protein misfolding and aggregation.